Galderma's tariff hedge costs about 6% of its U.S. sales a year

Start with the stock rather than the ribbon cutting. A closing position of $5.86tn after a $266bn increase implies a base near $5.594tn ^[13], which is a year of roughly 4.8% growth ^[14] in a series that measures accumulated book value rather than fresh concrete. Galderma's commitment is 0.24% of that annual increase ^[15]; you would need about 409 identical announcements to account for the year ^[16]. That is not an argument against the trend, only against reading one factory tour as its cause.

Now the hedge itself. Galderma turned over $5.24bn last year with the United States at 40% of sales, so roughly $2.10bn of American revenue ^[17]. Spread the more than $650m across the five years to 2030 and it is around $130m a year ^[18], about 6.2% of current U.S. sales annually ^[19] and 31% of a single year's American revenue in total ^[20]. That is a serious number for a company of that size and a modest one as insurance on $2.1bn of turnover, and the modesty is the interesting part, because the cost of building where you sell has fallen low enough that the decision stops being primarily financial. Flemming Ornskov's own framing is blunter than any spreadsheet: if you want to succeed, you have to succeed in the U.S. ^[10].

Which is why I would watch the org chart harder than the capex line. Research and development left Fort Worth for Boston because Ornskov wanted to recruit against Sanofi, whose Dupixent competes with Galderma's Nemluvio ^[8]; U.S. headquarters went to Miami for the consumer market and the route into Latin America, Orange County got a presence because aesthetics expertise concentrates there, and Fort Worth kept distribution ^[9]. Scientists and country managers are harder to unwind than a construction schedule, and they are the part of this that a change in duty rates will not reverse.

The counter-thesis sits in the same interview. The binding constraint Ornskov names is regulatory, the U.S. approval bar for aesthetic products being by far the highest and getting tougher ^[11], which means new domestic lines earn nothing until a reviewer clears the products meant to fill them. And his stated scoreboard is share against AbbVie-owned Allergan Aesthetics, the Botox and Juvederm owner he says he must catch before claiming success ^[7]. Tariffs sit on the cost line; share sits on the revenue line, and $130m a year of capacity does not move it.

This is probably wrong, but the honest read is that the $650m is an entry fee for the deepest consumer market rather than a tariff instrument, since Fortune's own list of motives puts market access, capital and talent ahead of the hedge ^[6]. It would be proved wrong if Galderma takes measurable share off Allergan while spending at this rate, which would make the plant the cheapest customer acquisition in aesthetics; it holds if 2030 arrives with the capacity built, the gap intact, and policymakers still counting the announcement as a tangible win ^[12]. On the morning the interview ran, equities were down worldwide as bond yields edged higher ^[21], which is the sort of tape that makes a spending commitment dated 2030 easier to stretch than to accelerate.